Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Date
2012
Author
Janssen, Harry L. A.
Ferenci, Peter
Brunetto, Maurizia R.
Lanza, A. Galeota
Messina, Vincenzo
Iannacone, Claudio
Massetto, Benedetta
Regep, Loredana
Colombo, Massimo
Lampertico, Pietro
Tabak, Fehmi
Cakaloglu, Yilmaz
Rijckborst, Vincent
Hansen, Bettina E.
Metadata
Show full item record
Abstract
Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with <2 log hepatitis B virus (HBV) DNA decline at week 12 of a 48-week peginterferon alfa-2a (PEG-IFN) treatment course achieved a sustained response (SR). We aimed at validating this stopping rule in two independent trials.
URI
http://hdl.handle.net/20.500.12627/111475
https://doi.org/10.1016/j.jhep.2011.12.007
Collections